🇺🇸 FDA
Pipeline program

GABITRIL (tiagabine hydrochloride; CEP-6671)

C6671A/301/AX/US

Phase 3 small_molecule completed

Quick answer

GABITRIL (tiagabine hydrochloride; CEP-6671) for General Anxiety Disorder is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
General Anxiety Disorder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials